Exploring the 'Davids and Goliaths' of therapeutic molecules

Featured In: Disease Research

By EurekAlert Thursday, April 8, 2024

Loading...

Two research units under Singapore's Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Singapore Immunology Network (SIgN), are collaborating with Italy's Siena Biotech S.p.A. to develop new drugs and targeted antibodies respectively, which will potentially help millions of cancer and bone loss patients across the world. This is the fifth major collaboration A*STAR has with research centres and universities in Italy .

Small molecule for cancer therapy

ETC and Siena Biotech are developing molecular inhibitors of a major signalling pathway in oncology to target difficult-to-treat forms of cancer such as gastric cancer, leukaemia and brain tumours. During this collaboration, up to six groups from ETC and some 30 scientists from Siena Biotech will be conducting tests on synthetic compounds to characterise and optimise their inhibitor function in cancer cells. A drug is expected to enter clinical trials in 2011.

Targeted forms of cancer therapy have gained significant interest since the late 1990s. They employ small molecules that inhibit mutated, overexpressed, or otherwise critical proteins characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing of all rapidly dividing cells within the body. ETC and Siena Biotech's molecular inhibitors may improve the prognosis for a very significant number of cancer patients, given that gastric cancer is the fourth most common cancer in the world and the second leading cause of cancer death. Gastric cancer is also one of the most common in Singapore (fifth highest in men and seventh highest in women, according to the Singapore Cancer Registry), with over 600 cases diagnosed every year.

"ETC is committed to translating early-stage scientific discoveries into practical applications," said Prof Alex Matter, CEO of ETC and leader of the research team that discovered the first targeted anti-cancer drug, Gleevec . "Leveraging on our technological know-how and the industry experience of Siena Biotech, we expect our partnership to spark new breakthroughs for cancer research. We especially appreciate the power of collaboration in the dynamic arena of cancer drug discovery."

Large molecule to treat bone diseases

SIgN and Siena Biotech are jointly developing a novel monoclonal antibody applicable to bone diseases such as osteoporosis. Under the agreement, Siena Biotech will characterise, develop and test the effectiveness of the monoclonal antibodies while SIgN will isolate the disease-specific human monoclonal antibody from a pool of tens of billions of polyclonal antibodies.

SIgN and Siena Biotech's antibody is another example of the world-class research being done on targeted disease therapies. The monoclonal antibody is intended to block a specific extracellular component in the molecular pathway that leads to bone loss, and thus stop the disease progression. If successful, it would reduce the risk of bone fractures and hence the associated healthcare costs for those suffering from various forms of bone frailty. Osteoporosis alone is estimated to afflict 1 in 3 women and 1 in 12 men over the age of 50 worldwide.

SIgN Chairman, Prof Philippe Kourilsky commented, "It is thanks to the excellent relationship that Singapore shares with Italy that we can collaborate in the often-neglected area of bone and tissue loss. Together with Siena Biotech, we will be using some of the world's most advanced molecular biology and antibody engineering techniques to hopefully make good progress in this area of research, and meet the dire healthcare needs of the world's ageing population."

"The strong synergies derived from shared commitment and knowledge coupled with complementary technology platforms between ETC, SIgN, and Siena Biotech will accelerate the development of novel therapies in difficult to treat diseases making them quickly available to the patients," said Dr Giovanni Gaviraghi, CEO of Siena Biotech.

"We are delighted that new scientific collaborations have been agreed between Siena Biotech and A* STAR. The common vision between A* STAR and the Fondazione Monte dei Paschi di Siena, to evolve and develop of their local economies, has been one of the pillars of the collaboration which we hope will bring new and effective medicines to the patients," added Marco Parlangeli, President of Siena Biotech and General Manager of Fondazione Monte Paschi di Siena.

SOURCE

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Successful Sample Identification

Apr 1

2D Barcodes ensure that a multitude of samples can be tracked in a variety of storage conditions.

Multi-Parametric Cellular Analysis

Mar 23

Flow cytometers perform a variety of multi parametric applications and have been used for an expanding set of cell analysis applications over the past forty years.

Maintaining a Healthy Cell Culture Environment

Mar 23

Investing in best practices and products at the beginning of any experiment is the most time- and cost-effective way to approach cell culture.

Publishing Data That Conform to the MIQE Guidelines

Jan 22

Minimum information for publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines help researchers design qPCR experiments.

Step up to the MIQE

Mar 30

Over the years, polymerase chain reaction (PCR) has evolved into a readily automated, high throughput quantitative technology. Real-time quantitative PCR (qPCR) has become the industry standard for the detection and quantification of nucleic acids for multiple application, including quantification of RNA levels. But a lack of consensus among researchers on how to best perform and interpret qPCR experiments presents a major hurdle for advancement of the technology. This problem is exacerbated by insufficient experimental detail in published work, which impedes the ability of others to accurately evaluate or replicate reported results.

Fast Optimization of a Multiplex Influenza Identification Panel Using a Thermal Gradient

Mar 30

The year 2009 was marked by the emergence of a novel influenza A (H1N1) virus that infects humans. There is a need to identify the different strains of influenza virus for purposes of monitoring the H1N1 strain pandemic and for other epidemiological and scientific purposes.

Advantages of Monolithic Laser Combiner Technology in Confocal Microscopy Systems

Jan 6

Fluorescence microscopy techniques require a reliable light source at the desired wavelength or wavelengths, with minimal downtime for maintenance and alignment. Lasers are a popular light source, although the alignment and upkeep of laser combiners is a time-consuming prospect for many users.

Size-Exclusion Chromatography for Purification of Biomolecules

Dec 2 2009

Size-exclusion chromatography (SEC) is a popular method to separate biomolecules based on their size. Primarily, it is applied to the separation of biopolymers such as proteins and nucleic acids, i.e. water-soluble polymers.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Type D personality among noncardiovascular patient populations: a systematic review.

Mar 30

OBJECTIVE: This article reviews all available literature concerning the implications of Type D personality (the conjoint effects of negative affectivity and social inhibition) among patients with noncardiovascular conditions. METHODS: Published papers were included if they...

STAT3 polymorphisms linked with idiopathic recurrent miscarriages.

Mar 30

PROBLEM: We investigated the association of signal transducers and activators of transcription (STAT)3 gene variants with idiopathic recurrent miscarriage (RM). METHOD OF STUDY: A case-control study involving 189 RM patients and 244 control women was carried out. STAT3...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Neuroscience Diseases of The Brain and How The Mind Emerges

Neuroscience Diseases of The Brain and How The Mind Emerges

Nov 8 2009

Dennis Choi, director of Emory Universitys Neuroscience Center, is renowned for his groundbreaking research on brain and spinal cord injury.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Information: